Herke specializes in venture capital, private equity, mergers & acquisitions, joint ventures and advises clients on corporate governance and other corporate law issues.
Herke has a broad transactional and corporate advisory practice across a wide range of sectors. She has a particular interest in transactions in healthcare and life sciences and digital sectors. Clients include national and international private equity and venture capital firms, investment funds and national and international corporate clients.
Herke is a graduate of the University of Utrecht, studied law at Panthéon-Assas in Paris, and was admitted to the Dutch bar in 1996. Prior to joining Osborne Clarke in December 2015, Herke was Counsel at Clifford Chance LLP in Amsterdam where she worked for 15 years.
Over the course of her career Herke worked from Amsterdam, London and Kuala Lumpur.
Legal 500 mentions Herke as a ‘Highly talented, pragmatic’ healthcare and life sciences expert and reported her as 'skilled, supportive'.
Herke is recognised by Client Choice in 2019 for her excellence in client service.
Herke has registered the following principal (and secondary) legal practice areas in the Netherlands Bar’s register of legal practice areas (rechtsgebiedenregister):
- Corporate Law
- Associations and Foundations
- Mergers and Acquisitions
- Director's liability
Based on this registration, she is required to obtain ten training credits per calendar year in each registered principal legal practice area in accordance with the standards set by the Netherlands Bar.
Advised HH Global, an award winning leading independent marketing execution partner to global brands in over 40 countries employing over 850 employees, with its acquisition of PostNL Print Management, the print management arm of the Dutch postal and logistic solutions provider PostNL, to help support HH Global’s growth in the Netherlands.
Represented Gilde Healthcare and key management (sellers) in the auction sale of ViroClinics Biosciences B.V. to Parcom Capital, a leading mid-market private equity firm in the Benelux, as well key management in their continuing investment in ViroClinics post-closing.